2018 AANS Annual Scientific Meeting-605. Study of Thymosin alpha 1 and its effect in postoperative ICH patients

605. Study of Thymosin alpha 1 and its effect in postoperative ICH patients

Video Transcription

Video Summary

Dr. Shrestha presents his research on Thymosin Alpha-1 and its effects on post-operative intracranial hemorrhage (ICH) patients. ICH is a public health issue with a high mortality rate. The study involved 80 post-operative patients at West China Hospital from March 2014 to May 2015. Patients were divided into a Thymosin group and a control group. The Thymosin group received Thymosin Alpha-1 subcutaneously for three weeks, while the control group received a saline solution. The Thymosin group had lower mortality (2% vs 10%) and infection rates (5% vs 30%). Thymosin appeared to increase interleukin-2R levels and T lymphocytes, potentially reducing postoperative pneumonia risk. Limitations include small sample size and study design variability. Overall, Thymosin Alpha-1 showed promise as an immunomodulator for ICH patients.

Asset Caption

Rajendra Shrestha, MBBS PhD (Nepal)

Keywords

Thymosin Alpha-1

post-operative intracranial hemorrhage

mortality rate

Thymosin group

interleukin-2R levels